Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03891953
Title Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

lung non-small cell carcinoma

melanoma

colorectal cancer

Advanced Solid Tumor

nasopharynx carcinoma

triple-receptor negative breast cancer

Therapies

DKY709

DKY709 + Spartalizumab

Age Groups: adult | senior
Covered Countries USA | ESP | DEU

Facility Status City State Zip Country Details
Massachusetts General Hospital Massachusetts Gen Hosp Recruiting Boston Massachusetts 02114 United States Details
Dana Farber Cancer Institute Recruiting Boston Massachusetts 02115 United States Details
Sarah Cannon Research Institute Drug Ship - 3 Recruiting Nashville Tennessee 37203 United States Details
Novartis Investigative Site Recruiting Dresden 01307 Germany Details
Novartis Investigative Site Recruiting Essen 45147 Germany Details
Novartis Investigative Site Recruiting Shatin, New Territories Hong Kong Details
Novartis Investigative Site Recruiting Chuo ku Tokyo 104 0045 Japan Details
Novartis Investigative Site Recruiting Barcelona Catalunya 08035 Spain Details
Novartis Investigative Site Recruiting Taipei 10002 Taiwan Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field